Two case reports: EML4-ALK rearrangement large cell neuroendocrine carcinoma and literature review

Two case reports: EML4-ALK rearrangement large cell neuroendocrine carcinoma and literature review

Anaplastic lymphoma kinase gene (ALK) rearrangement is present in only approximately 5% of non-small cell lung cancers (NSCLCs) and is scarce in LCNEC patients. The conventional first-line treatment options are chemotherapy combined with immunotherapy or chemotherapy followed by palliative radiother...

Full description

Bibliographic Details
Main Authors:	Qin Chen, Jingjing Zhang, Xuan Wang, Wenkang Zong, Leina Sun, Jianwen Qin, Yan Yin
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2023-11-01
Series:	Frontiers in Oncology
Subjects:	large cell neuroendocrine carcinoma EML4-ALK rearrangement ALK-TKI inhibitor alectinib immunohistochemistry
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2023.1227980/full

Similar Items

Sequential ALK inhibitor treatment benefits patient with leptomeningeal metastasis harboring non‐EML4‐ALK rearrangements detected from cerebrospinal fluid: A case report
by: Zhaona Li, et al.
Published: (2020-01-01)

Potential Therapeutic Strategy for EGFR-Mutant Lung Cancer With Concomitant EML4-ALK Rearrangement—Combination of EGFR Tyrosine Kinase Inhibitors and ALK Inhibitors
by: Ming-Hung Huang, PhD, et al.
Published: (2022-11-01)

Changing ALK-TKI-Resistance Mechanisms in Rebiopsies of <i>ALK</i>-Rearranged NSCLC: <i>ALK</i>- and <i>BRAF</i>-Mutations Followed by Epithelial-Mesenchymal Transition
by: Edyta M. Urbanska, et al.
Published: (2020-04-01)

Comparative Efficacy and Safety of Lorlatinib and Alectinib for ALK-Rearrangement Positive Advanced Non-Small Cell Lung Cancer in Asian and Non-Asian Patients: A Systematic Review and Network Meta-Analysis
by: Koichi Ando, et al.
Published: (2021-07-01)

Alternative Treatment Options to ALK Inhibitor Monotherapy for EML4-ALK-Driven Lung Cancer
by: Savvas Papageorgiou, et al.
Published: (2022-07-01)

A patient with ALK‐positive lung adenocarcinoma who survived alectinib‐refractory postoperative recurrence for 4 years by switching to ceritinib
by: Yuki Matsumura, et al.
Published: (2021-08-01)

Case Report: A Novel Non-Reciprocal ALK Fusion: ALK-GCA and EML4-ALK Were Identified in Lung Adenocarcinoma, Which May Respond to Alectinib Adjuvant-Targeted Therapy
by: Xiaoqian Zhai, et al.
Published: (2022-01-01)

Targeting ALK in Neuroendocrine Tumors of the Lung
by: Dilara Akhoundova, et al.
Published: (2022-06-01)

An unresectable and metastatic intrahepatic cholangiocarcinoma with EML4-ALK rearrangement achieving partial response after first-line treatment with ensartinib: a case report
by: Senmiao Huang, et al.
Published: (2023-08-01)

ALK-R3HDM1 and EML4-ALK fusion as a mechanism of acquired resistance to gefitinib: A case report and literature review
by: Zhu Zeng, et al.
Published: (2022-10-01)

ALK Rearrangement–Positive Pancreatic Cancer with Brain Metastasis Has Remarkable Response to ALK Inhibitors: A Case Report
by: Kai Ou, et al.
Published: (2021-09-01)

A Polytherapy Strategy Using Vincristine and ALK Inhibitors to Sensitise EML4-ALK-Positive NSCLC
by: Josephina Sampson, et al.
Published: (2022-02-01)

NGS‐based liquid biopsy profiling identifies mechanisms of resistance to ALK inhibitors: a step toward personalized NSCLC treatment
by: Estela Sánchez‐Herrero, et al.
Published: (2021-09-01)

Mechanisms of Acquired Resistance to ALK Inhibitors and the Rationale for Treating ALK-positive Lung Cancer
by: Hideko Isozaki, et al.
Published: (2015-04-01)

First-Line Treatment of ALK-Positive NSCLC
by: Hasna Bouchaab
Published: (2019-11-01)

Novel NLRC4‐ALK and EML4‐ALK double fusion mutations in a lung adenocarcinoma patient: A case report
by: Xueqian Wu, et al.
Published: (2020-06-01)

PI3Kβ inhibition enhances ALK‐inhibitor sensitivity in ALK‐rearranged lung cancer
by: Sarang S. Talwelkar, et al.
Published: (2023-05-01)

Exceptional response to alectinib for duodenal carcinoma with ALK fusion: A case report and literature review
by: Yuri Isaka, et al.
Published: (2023-01-01)

Pathological complete response to long-course neoadjuvant alectinib in lung adenocarcinoma with EML4-ALK rearrangement: report of two cases and systematic review of case reports
by: Liang Shi, et al.
Published: (2023-06-01)

Successful Alectinib Treatment for Carcinoma of Unknown Primary with <i>EML4-ALK</i> Fusion Gene: A Case Report
by: Keiji Sugiyama, et al.
Published: (2021-05-01)

Vulnerability of drug‐resistant EML4‐ALK rearranged lung cancer to transcriptional inhibition
by: Athanasios R Paliouras, et al.
Published: (2020-07-01)

Frequency of EGFR Mutation and EML4-ALK fusion gene in Arab Patients with Adenocarcinoma of the Lung
by: Shafik Hanan Ezzat, et al.
Published: (2015-06-01)

STK3-ALK, a Novel ALK Rearrangement in Non-Small Cell Lung Cancer With Sensitivity to Tyrosine Kinase Inhibitors: A Case Report
by: Chunlai Feng, et al.
Published: (2021-08-01)

Sustained Improvement in the Management of Patients with Non-Small-Cell Lung Cancer (NSCLC) Harboring ALK Translocation: Where Are We Running?
by: Gianluca Spitaleri, et al.
Published: (2023-05-01)

Durable Complete Response to Alectinib in a Lung Adenocarcinoma Patient With Brain Metastases and Low-Abundance EML4-ALK Variant in Liquid Biopsy: A Case Report
by: Yingying Zhu, et al.
Published: (2020-07-01)

Value of Immunohistochemical Methods in Detecting EML4-ALK Fusion Mutations:  A Meta-analysis
by: Chang LIU, et al.
Published: (2016-01-01)

Case Report: ALK rearranged locally advanced lung adenocarcinoma showing inconsistent radiographic findings and pathological responses during neoadjuvant alectinib therapy
by: Peijun Cao, et al.
Published: (2023-08-01)

Oncogene addiction and radiation oncology: effect of radiotherapy with photons and carbon ions in ALK-EML4 translocated NSCLC
by: Ying Dai, et al.
Published: (2018-01-01)

Identification and therapeutic evaluation of ALK rearrangements in non‐small‐cell lung cancer
by: Ruiying Zhao, et al.
Published: (2022-11-01)

Major pathologic response to alectinib in ALK-rearranged adenocarcinoma of the lung
by: Naoko Imanishi, et al.
Published: (2018-03-01)

A Case of Non-small Cell Lung Cancer Treated with Three ALK Inhibitors  and Chemotherapy
by: Jue WANG, et al.
Published: (2021-05-01)

Primary resistance to alectinib in a patient with STRN‐ALK‐positive non‐small cell lung cancer: A case report
by: Kunyan Sun, et al.
Published: (2021-06-01)

Overcoming Central β-Sheet &num;6 (Cβ6) ALK Mutation (L1256F), TP53 Mutations and Short Forms of EML4-ALK v3/b and v5a/b Splice Variants are the Unmet Need That a Re-Imagined 5th-Generation (5G) ALK TKI Must Deliver
by: Lee ATM, et al.
Published: (2024-02-01)

Evaluation of Efficacy of ALK Inhibitors According to Body Mass Index in ALK Rearranged NSCLC Patients—A Retrospective Observational Study
by: Marco Siringo, et al.
Published: (2023-06-01)

ALK‐rearranged lung adenocarcinoma resistant to alectinib with cauliflower gingival metastasis responds to brigatinib
by: Lianxi Song, et al.
Published: (2022-04-01)

A case of lung adenocarcinoma harboring <it>EGFR</it> mutation and <it>EML4-ALK</it> fusion gene
by: Tanaka Hisashi, et al.
Published: (2012-11-01)

Clinical Meaning of EML4-ALK Fusion Gene in Non-small Cell Lung Cancer
by: Wei HAN, et al.
Published: (2013-02-01)

A New Target in Non-small Cell Lung Cancer: EML4-ALK Fusion Gene
by: Huijuan WANG, et al.
Published: (2011-06-01)

Analysis of EML4-ALK Gene Fusion Mutation in Patients  with Non-small Cell Lung Cancer
by: Xuzhou WANG, et al.
Published: (2015-02-01)

The Transcriptional Roles of ALK Fusion Proteins in Tumorigenesis
by: Stephen P. Ducray, et al.
Published: (2019-07-01)